In the third quarter of 2023, BioInvent achieved a significant landmark with the recruitment of the first patient to the BI-1808 single agent Phase 2a study.
LUND, SE / ACCESSWIRE / October 26, 2023 / BioInvent International (STO:BINV)
“In the third quarter of 2023, BioInvent achieved a significant landmark with the recruitment of the first patient to the BI-1808 single agent Phase 2a study. BI-1808 can potentially become a novel checkpoint inhibitor and thus play an important role in the context of immune oncology. BioInvent is leading the field of companies aiming to unlock the value of TNFR2 in cancer therapy.” - Martin Welschof, CEO of BioInvent.
EVENTS IN THE THIRD QUARTER
• BioInvent announced it will hold two poster presentations at SITC 38th Annual Meeting in November 2023; single agent data for BI-1808 and preclinical data for BI-1910
• The first patient was recruited in the Phase 2a trial of single agent BI-1808 for the treatment of advanced malignancies
• The subcutaneous arm of Phase 1/2 trial with BI-1206 in solid tumors was initiated
• A research milestone event was achieved in the collaboration with Exelixis, triggering a USD 1 million milestone payment
• The dose-escalation part of the BI-1607 study was completed without any safety concerns. First clinical data to be presented at the San Antonio Breast Cancer Symposium on December 6, 2023.
EVENTS AFTER THE END OF THE PERIOD
• BioInvent and Transgene announced that the first patient had been treated in Part B of Phase 1 trial assessing the novel oncolytic virus BT-001 in combination with KEYTRUDA® (pembrolizumab)
FINANCIAL INFORMATION
Third quarter 2023
• Net sales SEK 26.8 (17.9) million.
• Profit/loss after tax SEK -71.1 (-63.9) million.
• Profit/loss after tax per share before and after dilution SEK -1.08 (-1.00).
• Cash flow from operating activities SEK -106.2 (172.8) million.
January - September 2023
• Net sales SEK 56.1 (305.5) million.
• Profit/loss after tax SEK -233.1 (35.8) million.
• Profit/loss after tax per share before and after dilution SEK -3.55 (0.59).
• Cash flow from operating activities SEK -269.3 (30.4) million.
• Liquid funds, current and long-term investments as of September 30, 2023: SEK 1,357.5 (1,664.3) million.
The complete interim report is available for download below and on the company’s website under Financial reports.
INVITATION TO PRESENTATION OF THE INTERIM REPORT JAN - SEP 2023
BioInvent’s CEO Martin Welschof will present the report together with CFO Stefan Ericsson. The presentation will be held in English.
When: Thursday October 26 at 2:00 pm CEST
Listen to the presentation webcast: https://ir.financialhearings.com/bioinvent-q3-report-2023
To participate via teleconference, please register via the following link: https://conference.financialhearings.com/teleconference/?id=5002417.
Upon registration, a phone number and conference ID for the conference call will be provided. You can ask questions verbally via the telephone conference.
The conference call will be made available on the company website after the call.
About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company’s validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline and providing licensing and partnering opportunities.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company’s fully integrated manufacturing unit. More information is available at www.bioinvent.com. Follow on social media platform X: @BioInvent.
For further information, please contact:
Cecilia Hofvander, Senior Director Investor Relations
Phone: +46 (0)46 286 85 50
Email: cecilia.hofvander@bioinvent.com
BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com
Attachments
SOURCE: BioInvent International
View source version on accesswire.com:
https://www.accesswire.com/796698/bioinvent-international-ab-interim-report-januaryseptember-2023
